Table 1 Clinical trial data analysed

Study	Phase	Study question	BID RT	Concurrent systemic agent	Number of analysable subjects	BED	Acute neurological toxicity	Late neurological toxicity	Overall toxicity	Survival	Ref.
8302	I/II	Hyperfractionated RT, dose escalation	Y	BCNU	756	73.6–114.2	86	9	Acceptable	HC	(Curran et al, 1992)
8409	I/II	Role of AZQ	N	AZQ	54	74–95	11	0	NR	HC	(1998)
9006	III (R)	Conventional vs hyperfractionated RT	Y/N	BCNU	693	100–100.8	28	15	NR	HC	(Scott et al, 1998a)
9305	III (R)	Radiosurgical boost	N	BCNU	187	100, >120	6	4	Acceptable	HC	(Souhami et al, 2004)
9411	II	Dose escalation for small tumours	Y	BCNU	105	98.1–108	5	3	Acceptable	HC	(Coughlin et al, 2000)
9417	II	Role of tirapazamine	N	Tirapazamine	122	100	3	1	More toxicities at higher dose	HC	(Del Rowe et al, 2000)
9513	II	Role of topotecan	N	Topotecan	84	100	4	3	Significant haematological toxicity	HC	(Fisher et al, 2002)
9602	II	Role of paclitaxel	N	Paclitaxel	61	100	1	4	Acceptable	HC	(Langer et al, 2001)
9710	II	Role of beta-interferon	N	Beta-interferon	55	100	1	2	Acceptable	HC	(Colman et al, 2006)
9803	I/II	Conventional fractionation, dose escalation	N	BCNU	203	110–140	10	13	Acceptable	HC	(Tsien et al, 2009)
9806	II	Role of thalidomide	N	Thalidomide	125	100	19	12	Acceptable	Slightly better than HC	(Yung et al, 2001)
0013	II	Intra-tumoral bleomycin	N	Bleomycin	14	100	1	4	—^a	—^a	—^a
0021	II	Role of tamoxifen	N	Tamoxifen	75	100	2	4	Acceptable	HC	(Robins et al, 2006)
0023	II	Role of stereotactic RT boost	N	BCNU	76	172	5	9	Acceptable	HC	(Cardinale et al, 2006)

Abbreviations: AZQ=diaziquone; BCNU=carmustine; BED=biological-equivalent dose; BID=twice daily radiation; HC=historical controls; N=no; NR=not reported; R=randomised; RT=radiation therapy; Y=yes.
^aSmall study, never published.

Quick links

Search